Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06389487 · ClinicalTrials.gov registry record · Phase 3
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,459
- Enrollment target
NCT06389487 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,459 participants.
The verdict
NCT06389487, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,459 participants
- Enrollment target
Study Summary
The aim of this study is to demonstrate the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in non-immunocompromised adults 18-49 years of age (YOA), who are at increased risk (AIR) for RSV disease, compared to older adults (OA) 60 YOA and above.
Interventions
- BIOLOGICAL RSVPreF3 OA investigational vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,459 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2025-03-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06389487
The ClinicalTrials.gov registry entry for NCT06389487 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,459 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RSVPreF3 OA investigational vaccine is the first listed.
NCT06389487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06389487 about?
NCT06389487 is a clinical study titled "A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above". The aim of this study is to demonstrate the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in non-immunocompromised adults 18-49 years of age (YOA), who are at increased risk (AIR) for RSV disease, compared to older adults (OA) 60 YOA and above.
What is the current status of trial NCT06389487?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,459 participants. The study started on 2024-04-29. Estimated completion is 2025-03-18.
What interventions are being tested in trial NCT06389487?
The interventions under investigation include: RSVPreF3 OA investigational vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06389487?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.